An Open-label Safety and Efficacy Study of Recombinant FVIII in Patients With Severe Hemophilia A

Study Site 3720002, Dublin

Study Site 0400001, Vienna

Study Site 0400002, Vienna

Study Site 7100001, Parktown

Study Site 0360014, Melbourne

Study Site 5280007, Utrecht

Study Site 0400003, Linz

Study Site 3480007, Debrecen

Study Site 6080001, Cebu City

Study Site 7560010, Lucerne

Study Site 5280008, Nijmegen

Study Site 6080002, Davao City

Study Site 0400012, Graz

Study Site 7640001, Bangkok

Study Site 7640005, Bangkok

Study Site 7240008, A Coruña

Study Site 3800023, Milan

Study Site 7240007, Madrid

Study Site 2500015, Brest

Study Site 2760066, Hanover

Study Site 8400116, Miami

Study Site 2760087, Giessen

Study Site 7640004, Khon Kaen

Study Site 2500018, Nantes

Study Site 7240023, Valencia

Study Site 8040007, Dnipropetrovsk

Study Site 7640002, Chiang Mai

Study Site 4580001, Kuala Lumpur

Study Site 2760034, Bonn

Study Site 8400154, Milwaukee

Study Site 2500028, Lille

Study Site 2760091, Frankfurt

Study Site 8400184, Chicago

Study Site 8400204, New Orleans

Study Site 2500002, Paris

Study Site 8400041, Houston

Study Site 8040005, Lviv

Study Site 8400241, Aurora

Study Site 7640003, Songkhla

Study Site 2500017, Le Kremlin-Bicêtre

Study Site 4220007, Beirut

Study Site 6420037, Timișoara

Study Site 8400213, San Diego

Study Site 8400118, Hartford

Study Site 8400240, Dallas

Study Site 0360028, Nedlands

Study Site 0360031, Perth

Study Site 1240022, Saint John

Study Site 2030017, Hradec Králové

Study Site 2680001, Tbilisi

Study Site 3920031, Hyōgo

Study Site 3920029, Nagoya

Study Site 3920064, Okayama

Study Site 3920033, Saitama

Study Site 3920025, Tokyo

Study Site 5280006, Amsterdam-Zuidoost

Study Site 6160013, Gdansk

Study Site 6160038, Krakow

Study Site 6160035, Rzeszów

Study Site 6160014, Wroclaw

Study Site 6200001, Porto

Study Site 6420030, Bucharest

Study Site 7240021, Barcelona

Study Site 8260008, London